文献速递乳腺癌

哌柏西利联合依西美坦及GnRH激动剂对比卡培他滨治疗绝经前HR阳性HER2阴性转移性乳腺癌:KCSG-BR15-10随机II期试验

Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2019-10-24

这项多中心开放随机II期研究纳入既往他莫昔芬治疗失败的绝经前HR阳性HER2阴性转移性乳腺癌患者,比较哌柏西利联合依西美坦及GnRH激动剂与卡培他滨的疗效和安全性。

要点

  • 联合内分泌组3级及以上中性粒细胞减少发生率为75%,高于卡培他滨组的16%。
  • 该联合方案可作为他莫昔芬经治的绝经前HR阳性HER2阴性转移性乳腺癌治疗选择。

核心结论

  • 在绝经前HR阳性HER2阴性转移性乳腺癌患者中,哌柏西利联合依西美坦及卵巢功能抑制相比卡培他滨显著改善无进展生存期。

研究设计与样本

  • 多中心开放标签随机II期研究,在韩国14家学术机构开展,纳入189例患者,184例随机分配至哌柏西利联合内分泌组或卡培他滨组。
  • 主要终点为无进展生存期,分析采用改良意向治疗人群,排除未接受研究药物治疗的患者。

主要发现

  • 治疗相关3级及以上中性粒细胞减少在联合内分泌组为69/92(75%),卡培他滨组为14/86(16%)。
  • 治疗相关严重不良事件在联合内分泌组为2/92(2%),卡培他滨组为15/86(17%),无治疗相关死亡。

关键数值与推荐

  • 纳入标准:绝经前女性,年龄19岁及以上,HR阳性HER2阴性乳腺癌,既往他莫昔芬治疗期间复发或进展,ECOG体能状态0-2,允许一线既往转移性化疗。
  • 卡培他滨方案:口服1250mg/m2每日两次,用2周停1周,每3周为一周期。
  • 随机分层因素:既往转移性化疗和内脏转移。

临床怎么用

  • 对于他莫昔芬经治的绝经前HR阳性HER2阴性转移性乳腺癌患者,哌柏西利联合依西美坦及卵巢功能抑制可作为卡培他滨化疗的替代选择。
  • 使用该联合方案时需密切监测中性粒细胞减少,尽管严重不良事件发生率低于卡培他滨组。

局限性

  • 本研究为II期开放标签试验,样本量有限。
  • 总生存数据尚未成熟,研究仍在随访中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endocrine treatment is recommended by clinical guidelines as the preferred treatment option for premenopausal as well as postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. In real-world clinical practice, however, a substantial number of patients are treated with chemotherapy. We aimed to compare the clinical antitumour activity and safety of palbociclib plus endocrine therapy with that of capecitabine chemotherapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. METHODS: This multicentre, open-label, randomised, phase 2 study was done in 14 academic institutions in South Korea. Premenopausal women aged 19 years or older with hormone receptor-positive, HER2-negative breast cancer that had relapsed or progressed during previous tamoxifen therapy and with an Eastern Cooperative Oncology Group performance status of 0-2 were included. One line of previous chemotherapy for metastatic breast cancer was allowed. Patients were randomly assigned, using a random permuted block design (with a block size of two), to receive palbociclib plus combination endocrine therapy (oral exemestane 25 mg per day for 28 days and oral palbociclib 125 mg per day for 21 days every 4 weeks plus leuprolide 3·75 mg subcutaneously every 4 weeks) or chemotherapy (oral capecitabine 1250 mg/m2 twice daily for 2 weeks every 3 weeks). Randomisation was stratified by previous chemotherapy for metastatic breast cancer and visceral metastasis. The primary endpoint was progression-free survival. All analyses were done in a modified intention-to-treat population that excluded patients who did not receive study medication. This study is registered with ClinicalTrials.gov, NCT02592746, and is ongoing for follow-up of overall survival. FINDINGS: Between June 15, 2016, and Dec 10, 2018, 189 patients were enrolled, of whom 184 were randomly assigned to the palbociclib plus endocrine therapy group (n=92) or the capecitabine group (n=92). Six patients in the capecitabine group withdrew from the study before drug administration; therefore, 92 patients in the palbociclib plus endocrine therapy group and 86 patients in the capecitabine group were included in the modified intention-to-treat analyses. 46 (50%) of 92 patients in the palbociclib plus endocrine therapy group and 45 (51%) of 92 in the capecitabine group were treatment naive for metastatic breast cancer. During a median follow-up of 17 months (IQR 9-22), median progression-free survival was 20·1 months (95% CI 14·2-21·8) in the palbociclib plus endocrine therapy group versus 14·4 months (12·1-17·0) in the capecitabine group (hazard ratio 0·659 [95% CI 0·437-0·994], one-sided log-rank p=0·0235). Treatment-related grade 3 or worse neutropenia was more common in the palbociclib plus endocrine therapy group than in the capecitabine group (69 [75%] of 92 vs 14 [16%] of 86 patients). 2 (2%) patients in the palbociclib plus endocrine therapy group and 15 (17%) patients in the capecitabine group had treatment-related serious adverse events. No treatment-related deaths occurred. INTERPRETATION: Exemestane plus palbociclib with ovarian function suppression showed clinical benefit compared with capecitabine in terms of improved progression-free survival in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Palbociclib plus exemestane with ovarian suppression is an active treatment option in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer who have been pretreated with tamoxifen. FUNDING: Pfizer, Shinpoong, and Daewoong Korea and Takeda.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Park YH, Kim TY, Kim GM, et al. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2019. PMID: 31668850. doi:10.1016/S1470-2045(19)30565-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。